Skip to main content

tavneos

tavneos: developed by 1 company · 1 FDA decision.

tavneos evidence translation

What we can confirm

What it means

Source-backed records connect tavneos to CCXI; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could tavneos → CCXI affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Lupus nephritis (LN)

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
ChemoCentryx, Inc. (CCXI)
Lupus nephritis (LN)
Preclinical
FDA Decisions1 records
NDA214487Type 1 - New Molecular EntityOrphan DrugStandardOralCapsule

Frequently asked questions

Who is developing tavneos?

tavneos is being developed by ChemoCentryx, Inc..

What is tavneos's latest FDA decision?

The most recent tracked FDA decision for tavneos is Approval, dated October 7, 2021.